DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: LEVEMIR

Summary for Tradename: LEVEMIR

Patents:11
Applicants:1
NDAs:1
Suppliers: see list3
2013 Sales:$1,547,629,000
drug
patent expirations by year for
 LEVEMIR

Pharmacology for Tradename: LEVEMIR

Ingredient-typeInsulin
Drug ClassInsulin Analog

Clinical Trials for: LEVEMIR

Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 1

Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 1

Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 1

Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes Mellitus
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 2

Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes
Status: Completed Condition: Type 2 Diabetes

Observational Study on Safety of Self-titration of Once Daily Levemir®
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 2

Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days
Status: Completed Condition: Alzheimer's Disease; Mild Cognitive Impairment

Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 2

Observational Study to Evaluate the Safety of Levemir® in Type 2 Diabetes
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 2

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo Nordisk Inc
LEVEMIR
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536Jun 16, 2005RXYes<disabled><disabled>
Novo Nordisk Inc
LEVEMIR
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536Jun 16, 2005RXYes<disabled><disabled>
Novo Nordisk Inc
LEVEMIR
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536Jun 16, 2005RXYes5,750,497<disabled>YY<disabled>
Novo Nordisk Inc
LEVEMIR
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536Jun 16, 2005RXYes5,866,538<disabled>YY<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc